Vicore Pharma Holding AB is a biotechnology company focused on developing innovative therapies for rare pulmonary diseases. Its lead asset, VC-01, targets severe pulmonary diseases and has shown promise in clinical trials, positioning the company uniquely within the niche market of pulmonary therapeutics.
Business Overview
Vicore Pharma primarily generates revenue through partnerships and collaborations in drug development, particularly in the area of pulmonary disease therapies. The company has a strong pipeline with potential for significant future revenue once products reach commercialization.
Clinical trial results for VC-01 and other pipeline candidates
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals from health authorities
Market sentiment regarding rare disease therapeutics
Risk Factors
Regulatory changes affecting drug approval processes
Technological disruption in biotechnology research
Emerging therapies from competitors targeting similar pulmonary diseases
Potential for larger pharmaceutical companies to dominate the market
High cash burn rate impacting liquidity
Dependence on external funding for R&D
Macro Sensitivity
low - The company operates in a niche market focused on rare diseases, which are less sensitive to economic cycles compared to broader healthcare sectors.
Interest rates have minimal direct impact on Vicore's operations, but higher rates could affect funding availability for biotech R&D, potentially increasing costs of capital.
minimal - The company has no debt, reducing its exposure to credit conditions.
Profile
growth - Investors are likely attracted to the potential high returns from successful drug development.
high - The stock exhibits high volatility due to the binary nature of clinical trial outcomes.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
